Overview
Status
Active
Registry date
2021-05-05
Share capital
5,550.00 PLN
Registered address
ul. Stanisława Żaryna 2B, 02-593 Warszawa, Poland
Electronic delivery address
AE:PL-85930-79323-IAUGJ-32
Financials
Revenue history (in k)
Filing timeliness
1 of 5 financial statements was filed late (for 2021, 91 days late).
- 202519/03/2026
- 202404/06/2025
- 202319/06/2024
- 202213/06/2023
- 202114/10/2022
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 10.40kMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD 4.57kMedianUSD -1.27kAverageUSD -93.01k
Operating costs
This companyUSD 5.50kMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 15.42kMedianUSD 134.71kAverageUSD 3.04m
Industry
Authorized Representatives
Wojciech Jacek Ciesielski age 44 – President of the Management Board
Manner of representation
The company is represented by the President of the Management Board independently, or by a member of the management board jointly with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 17 | $229.61 | 15.3153% | |
Magdalena Bujalska-Zadrożny age 54 | 20 | $270.12 | 18.018% |
Ryszard Nowaczyk age 68 | 12 | $162.07 | 10.8108% |
| 62 | $837.39 | 55.8559% |
Beneficial owners
| Person | Rights |
|---|---|
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Frontline Biosciences S.A. | $219,186.29 | frontlinebiosciences.com | ||
| AI Corelab sp. z o.o. | $128,365.55 | aicorelab.com | ||
| Modica P.S.A. | $103,400.72 | modica.bio | ||
| WPD Pharmaceuticals sp. z o.o. | $90,822.78 | wpdpharmaceuticals.com | ||
| WPD Pharmaceuticals S.A. | $87,561.70 | wpdpharmaceuticals.pl | ||
| Stenocoat sp. z o.o. | $36,665.21 | stenocoat.com | ||
| Platforma Badań Genetycznych sp. z o.o. | $28,558.39 | zdrowegeny.pl | ||
| Biosel sp. z o.o. | $19,100.32 | selol.pl | ||
| Omniseptica sp. z o.o. | $3,475.29 | omniseptica.com | ||
| Wavex Energy sp. z o.o. | $142.33 | wavexenergy.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-03-19 | Address change (Ul. Postępu 21b, 02-676, Warszawa → Ul. Stanisława Żaryna 2b, 02-593, Warszawa) | |
| 2025-08-14 | Share capital increase (5,450.00 PLN → 5,550.00 PLN) | |
| 2024-11-19 | Share capital increase (5,250.00 PLN → 5,450.00 PLN) | |
| 2024-10-08 | Share capital increase (5,100.00 PLN → 5,250.00 PLN) | |
| 2024-02-21 | Share capital increase (5,000.00 PLN → 5,100.00 PLN) |
FAQ
The main business activity of Bioxyma focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on May 5, 2021.
The headquarters is located at: ul. Stanisława Żaryna 2B, 02-593 Warszawa.
The management board consists of: Wojciech Jacek Ciesielski (President of the Management Board).
The share capital of the company is PLN 5,550 (approx. $1,499).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
The company reported a revenue of $10,402 in 2025, which is a decrease of 89.3% compared to 2024.
Yes, in 2025 the company was profitable, achieving a net profit of $4,571.
Last updated: 2026-03-22
